This study will evaluate long-term safety and tolerability of pelacarsen (TQJ230) 80 mg Once a month (QM) in patients with elevated Lp(a) and established ASCVD. All consenting participants from the parent study who meet the eligibility criteria will be participating in this open label extension study.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants who have provided informed consent prior to initiation of any study-specific activities/procedures.
Participants who have completed the parent study and received the assigned study treatment at the time of its completion
You may not be if
Participants who permanently discontinued the study treatment as mandated per protocol or due to adverse events in the parent study
Any medical condition(s) in the investigator's opinion that may put the participant at risk or interfere with the study participation
Participants who are receiving another investigational drug or device before the open-label treatment period
Participants who have a known sensitivity to the study drug and are deemed as unsuited for the study by the investigator
Clareo Health | Pelacarsen Roll-over Extension Program
